enGene Inc. Warrants (ENGNW)
0.68
0.00 (0.00%)
At close: Mar 25, 2025, 10:49 AM
0.00% (1D)
| Bid | n/a |
| Market Cap | 34.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 133 |
| Avg. Volume (20D) | 8,071.272 |
| Open | 0.70 |
| Previous Close | 0.68 |
| Day's Range | 0.68 - 0.70 |
| 52-Week Range | 0.68 - 0.70 |
| Beta | -0.61 |
About ENGNW
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ENGNW